drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T)
drug_description
An autologous, genetically engineered T-cell therapy in which patient T cells are modified to express a chimeric antigen receptor targeting Claudin 18.2, with an iPD-1 design intended to counter PD-1/PD-L1–mediated inhibition. Administered as a single intravenous infusion to promote tumor cell killing via T-cell activation and cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express a CAR targeting Claudin 18.2. Antigen engagement triggers T‑cell activation, proliferation, and cytotoxic killing of tumor cells. The iPD‑1 design counteracts PD‑1/PD‑L1–mediated inhibition in the tumor microenvironment to enhance T‑cell function and persistence.
drug_name
XKDCT086 (iPD-1-Claudin18.2 CAR-T)
nct_id_drug_ref
NCT05952375